Louisville, KYNCT06526338Now EnrollingIRB Ready

Hepatocellular Carcinoma Clinical Trial in Louisville, KY

Access cutting-edge hepatocellular carcinoma treatment through this phase 2 clinical trial at a research site in Louisville. Study-provided care at no cost to qualified participants.

Sponsored by Robert C. Martin

Quick Self-Assessment

See if you qualify for this Louisville location

Preparing your pre-screening questions…

Expert Care in Louisville

Access hepatocellular carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hepatocellular carcinoma treatment provided free

Apply for This Louisville Location

Check if you qualify for this hepatocellular carcinoma clinical trial in Louisville, KY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Louisville

    Convenient for KY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Louisville site if eligible
  4. 4Begin participation

About This Hepatocellular Carcinoma Study in Louisville

The purpose of this study is to evaluate the safety and efficacy of a single injection of IP-001 as adjuvant therapy after local ablation or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).

Sponsor: Robert C. Martin

Who Can Participate

Inclusion Criteria

Age ≥ 18 years at time of signing Informed Consent.
Has a diagnosis of hepatocellular carcinoma (HCC) documented radiologically by American Association for the Study of Liver Diseases (AASLD) criteria and/or histopathologically from a tumor biopsy.
Has a treatment plan to receive either a curative ablation (RFA or MWA) or a curative surgical resection and ablation.
Has HCC with intermediate, high or very high risk of recurrence.
Has hepatic only HCC (disease confined to the liver only), defined by no extra-hepatic lesions greater than 1 cm in size.
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Patient with past or ongoing hepatitis C virus (HCV) infection will be eligible if the patient has completed HCV treatment at least 1 month prior to Day 1.
Patient with controlled hepatitis B will be eligible if the patients meets the following criteria:
Antiviral therapy for hepatitis B virus (HBV) must be given for at least 4 weeks and HBV viral load must be less than 500 IU/mL prior to treatment. Patients on active HBV therapy with viral loads under 00 IU/mL should stay on the same therapy throughout study treatment.
Patients who are hepatitis B core antibody (anti-HBc) positive, negative for HBsAg, and negative or positive for anti- HBs, and who have an HBV viral load under 500 IU/mL do not require HBV anti-viral prophylaxis.
Has adequate organ function as specified in the Adequate Organ Function Laboratory Values Table. Specimens must be collected within 14 days prior to Day 1.

Exclusion Criteria

Known allergic reaction to shellfish, crabs, crustacean, or any trial components.
Has an active infection requiring systemic therapy.
Has a diagnosis of immunodeficiency or currently receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent), or any other form of immunosuppressive therapy within 7 days prior to treatment day (Day 1), or has plans to start treatment including \>10 mg daily of prednisone equivalent or any immunotherapy.
Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents or immunosuppressive drugs). NOTE: replacement therapy (e.g., thyroxine or insulin) is not considered a form of systemic treatment and is allowed.
Has had an allogenic tissue/solid organ transplant.
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, active tuberculosis, or idiopathic pneumonitis.
Has received local therapy to liver, ablation other than radiofrequency or microwave ablation (i.e., alcohol ablation, transcatheter chemoembolization, transcatheter embolization, hepatic arterial infusion, local radiation/Stereotactic Body Radiation Therapy or radioembolization) less than 3 months prior to treatment.
Is receiving any of the following prohibited concomitant therapies less than 21 days from treatment or 5 drug elimination half-lives, whichever is shorter prior to randomization:
Antineoplastic systemic chemotherapy or biological therapy.
Immunotherapy not specified in this protocol.
Systemic glucocorticoids for any purpose other than to modulate symptoms from an adverse event (AE) that is suspected to have an immunologic etiology. Inhaled or topical steroids are allowed, and systemic steroids at doses ≤10 mg/day prednisone or equivalent are allowed. Exception: steroids may be used for premedication prior to imaging.
Has received a live vaccine within 28 days prior to treatment Day 1.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Louisville?

Yes, this clinical trial (NCT06526338) has an active research site in Louisville, KY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hepatocellular Carcinoma Treatment Options in Louisville, KY

If you're searching for hepatocellular carcinoma treatment options in Louisville, KY, this clinical trial (NCT06526338) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Louisville research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced hepatocellular carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hepatocellular carcinoma clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Louisville, KY

See all liver cancer clinical trials recruiting in Louisville — not just this study.

Browse Liver Cancer Trials in Louisville →

Browse More Trials by Condition

Liver Cancer TrialsAll Conditions →

Ready to Join in Louisville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Louisville, KY